Results 11 to 20 of about 79,111 (213)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq

Journal of Pharmacy and Bioallied Sciences, 2023
ABSTRACTBackground:Clinical pharmacogenetics is a rapidly growing field that focuses on the study of genetic variations and their impact on drug metabolism, efficacy, and safety. Angiotensin II receptor blockers (ARBs) are commonly used to treat hypertension in Iraq but not all patients respond equally to these drugs.Aim:This article aims to review the
Hany A Al-Hussaniy, Alaa F Hassan, Amjad I Oraibi, Atheer M R. Al-Juhaishi, Fatima A Naji, Zahraa S Al-Tameemi   +5 more
openaire   +3 more sources

Olmesartan in Management of Proteinuria [PDF]

Journal of Clinical and Diagnostic Research, 2018
Proteinuria is a marker and predictor of cardiovascular morbidity and mortality. Blockade of angiotensin receptor might result in reduction in proteinuria.
Satyanarayan Routray, VN Shah, Abhay Sahoo, Priti Sanghavi, Amit Omprakash Gupta, Onkar C Swami   +5 more
doaj   +1 more source

Impaired endothelial function of the retinal vasculature in hypertensive patients [PDF]

, 2004
<p><b>Background and Purpose:</b> Arterial hypertension constitutes a central factor in the pathogenesis of stroke. We examined endothelial function of the retinal vasculature as a model of the cerebral circulation.</p> <p ...
Delles, C., Harazny, J., Hilgers, K.F., Michelson, G., Oehmer, S., Schmieder, R.E.   +5 more
core   +1 more source

Candesartan in nephrological practice

Počki, 2014
First-line drugs in the treatment of hypertension in patients with chronic kidney disease is an angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.
Ya.A. Dombrovskyi, D.D. Ivanov
doaj   +1 more source

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study [PDF]

, 2018
Aims: To test the prognostic value of emerging biomarkers in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial. Methods and results: Circulating cardiac [N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high ...
Alehagen, Arimoto, Balling, Bolignano, Cabassi, Dupont, Gaggin, Gravning, Grodin, Guisado Espartero, Haehling, Harrell, Jackson, Lassus, Lassus, Lok, Maisel, Maisel, McMurray, McMurray, Miller, Miller, Nagarajan, Park, Pascual-Figal, Pencina, Pencina, Pocock, Ponikowski, Rahimi, Rush, Shlipak, Swedberg, Tentzeris, Zamora   +34 more
core   +9 more sources

Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost

SAGE Open Medicine, 2014
Objectives: Combination therapy using an angiotensin II receptor blocker is expected to promote medication adherence and alleviate economic burden among patients by reducing the number of drugs taken, and thereby to lower associated medical costs. In the
Hitomi Teramachi, Tatsuya Takahashi, Tomoya Tachi, Yoshihiro Noguchi, Hiroyuki Nagasawa, Yoko Ino, Takashi Mizui, Chitoshi Goto, Teruo Tsuchiya   +8 more
doaj   +1 more source

Relationship between antihypertensive medications and cognitive impairment: Part II. Review of Physiology and animal studies [PDF]

, 2016
Purpose of Review There is an established association between hypertension and increased risk of poor cognitive performance and dementia including Alzheimer’s disease; however, associations between antihypertensive medications (AHM) and dementia risk are
Carlson, MC, Peters, J, Peters, R, Schuchman, M, Yasar, S   +4 more
core   +1 more source

Effects of angiotensin II receptor blockers on dementia [PDF]

Hypertension Research, 2009
The renin-angiotensin system (RAS) is involved in pathological mechanisms of target organ damage as well as the induction of hypertension; therefore, blockade of the RAS has been expected to prevent cardiovascular and cerebrovascular diseases beyond its antihypertensive effects.
Masaki, Mogi, Masatsugu, Horiuchi
openaire   +2 more sources

Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study [PDF]

, 2017
Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results:
Agewall, Stefan, Atar, Dan, Clark, Andrew L., Cleland, John G.F., Corletto, Anna, Frankenstein, Lutz, Fröhlich, Hanna, Goode, Kevin, Grundtvig, Morten, Henning, Felix, Hole, Torstein, Katus, Hugo A., Kazmi, Syed, Schellberg, Dieter, Täger, Tobias   +14 more
core   +1 more source

Angiotensin II Type 1 Receptor Blockers [PDF]

Circulation, 2001
In the 1970s, a series of observations demonstrated that angiotensin II has deleterious effects on the heart and kidney and that patients with high levels of plasma renin activity are at a higher risk of developing stroke or myocardial infarction than those with low plasma renin activity.1 2 Thereafter, the development of pharmacological probes that ...
openaire   +2 more sources